Revelation Biosciences, Inc. (REVB) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है San Diego, CA, United States. वर्तमान CEO हैं James Rolke.
REVB के पास है IPO तिथि 2020-11-17, 8 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Capital Marke, बाजार पूंजीकरण $4.46M.
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
